PET scanning has well recognized utility in staging and restaging lymphoma. It is now covered by CMS and recommended by recent literature. In regard to PET/CT, in a recent study, the addition of PET/CT to CT changed the management decisions in approximately a quarter of NHL and a third of HD patients, mostly in early disease stages. Thus, PET/CT performed as the initial staging procedure may well obviate the need for additional diagnostic CT in the majority of patients. Based on this, I consider PET/CT to be the same as PET for the purposes of this review. NCCN recommends PET for restaging of several lymphoma subtypes, such as Peripehral T-cell and large cell lymphoma.
Cancer Care Ontario (CCO). Diagnostic imaging in lymphoma. Toronto (ON): Cancer Care Ontario (CCO); 2006 Mar 8. 17 p. [18 references]Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781–1787.
Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?Ann Oncol. 2006 Jan;17(1):117-22
Shankar LK, Hoffman JM, Bacharach S, et al. Guidelines for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059–1066.